Oncology Nuclear Medicine Equipment Market Report: 6.2% CAGR in 2026 — PET/CT Ushers in a New Era of Precision Cancer Care

As the clinical adoption of precision medicine continues to advance globally, the oncology nuclear medicine equipment market is entering a new phase of structural growth. According to a study by YHResearch (Hengzhou Chengsi), the global oncology nuclear medicine equipment market reached approximately RMB 13.94 billion in 2025 and is expected to expand to nearly RMB 22.04 billion by 2032. The compound annual growth rate (CAGR) from 2026 to 2032 is projected at 6.2%. This report highlights market trends that are highly relevant to stakeholders in the medical device industry.

1. What Is Oncology Nuclear Medicine Equipment?

Oncology nuclear medicine equipment refers to specialized medical devices that use radioactive tracers for the diagnosis, staging, and treatment of malignant tumors. Major products include PET (positron emission tomography), PET/CT, PET/MR, gamma cameras, and radionuclide therapy systems.

These devices play a critical role in precision cancer care by enabling functional tumor imaging and targeted radionuclide therapy.

The key difference from conventional imaging equipment is that they do not merely visualize “where the tumor is located,” but also assess “what the tumor is doing” at the metabolic level. This provides essential information for treatment planning.

2. Market Data: Capacity, Pricing, and Profitability

In 2025, the global annual production capacity for oncology nuclear medicine equipment was approximately 1,950 units, with output of about 1,543 units, resulting in a capacity utilization rate of roughly 79%.

The global average selling price reached approximately USD 1.25 million per unit, placing the segment in the high-price, high-technology-barrier category of the medical device industry.

From a profitability perspective, gross margins among leading manufacturers are concentrated in the 45% to 65% range, significantly above the level seen in the broader medical device market. This indicates that the sector continues to offer substantial technological value-added.

In terms of product classification, the market can be broadly divided into fixed and mobile systems. By function, it is segmented into nuclear medicine diagnostic equipment, nuclear medicine therapeutic equipment, and integrated diagnostic-therapeutic nuclear medicine systems. Among these, functional imaging systems centered on PET have become the core of the market, supported by their superior diagnostic capabilities.

3. Major Application Areas and Deployment Scenarios

Oncology nuclear medicine equipment is not limited to a single clinical department; it is used across a wide range of healthcare settings.

The main end-use settings are as follows:

General Hospitals

PET/CT is deployed as a core device in nuclear medicine departments and is used for early cancer detection and treatment response evaluation.

Cancer Specialty Hospitals

These institutions are major customers for high-performance PET/MR systems, as they require advanced imaging accuracy and multimodality integration capabilities.

Radiation Therapy Centers

The integration of radionuclide therapy systems with high-precision radiotherapy platforms is giving rise to a new cancer treatment model.

Key evaluation criteria for healthcare institutions include image resolution, quantitative accuracy, radiation dose management, system stability, and regulatory compliance. As a result, competition among manufacturers is expanding beyond hardware performance to include image reconstruction algorithms and comprehensive service capabilities.

4. Industry Chain Analysis: From Crystal Materials to Clinical Application

A structural analysis of the industry chain is essential to understanding the market.

Upstream

This segment includes scintillator crystals, photodetectors, high-voltage power modules, superconducting magnets, precision electronic components, and radionuclide-related components. These areas have high technical barriers, and only a limited number of suppliers dominate the market.

Midstream

Equipment manufacturers are responsible for imaging system integration, detector design, software algorithm development, and system calibration. Major companies are concentrated in the United States, Europe, and China, with representative players including Siemens Healthineers, United Imaging, Neusoft Medical, Shinva Medical, and China Isotope & Radiation Corporation.

Downstream

The end customers are healthcare institutions, and equipment procurement is influenced by medical insurance systems, installation permit regulations, and hospital department planning.

5. Market Trends: Three Growth Drivers Reshaping the Industry Structure

Based on this market report and broader industry developments, the following three trends are expected to become increasingly prominent in the market after 2026.

Wider Adoption of AI Image Reconstruction Technologies

The integration of detector technology with AI algorithms is significantly improving diagnostic accuracy and operational efficiency, while also reducing dependence on operator experience.

Accelerated Multimodality Integration

Integrated systems such as PET/MR are expanding beyond university hospitals and large medical institutions into mid-sized hospitals. The market is shifting from “high-end substitution” to “broad-based upgrading.”

Growth in Emerging Markets

In Southeast Asia, India, and South America, ongoing improvements in healthcare infrastructure and nuclear medicine capabilities are becoming important drivers of market growth. Chinese companies such as United Imaging and Neusoft Medical are strengthening their competitiveness through high cost performance and localized service networks.

Conclusion: A Turning Point Toward the Era of Functional Imaging

What this market report reveals is not only the expansion of the market from RMB 13.94 billion to RMB 22.04 billion, but also a major industrial transformation in oncology care—from the era of anatomical diagnosis to the era of functional imaging.

Although a 6.2% CAGR is not explosive growth, it represents a highly stable growth trajectory for a medical device market characterized by high prices and significant technological barriers.

For those considering investment in or adoption of oncology nuclear medicine equipment, it is important to monitor the penetration rate of PET/CT and the commercialization progress of AI-based image reconstruction technologies. These two factors are likely to be the key drivers of market share reshuffling over the next three to five years.

The data in this article is based on YHResearch (Hengzhou Chengsi)’s “2026 Global and China Oncology Nuclear Medicine Equipment Industry Major Companies Market Share and Ranking Survey Report.” The report provides a comprehensive analysis of the global oncology nuclear medicine equipment market, including development trends, market size, market share, and competitive landscape, along with professional forecasts for the market outlook from 2026 to 2032. The historical data covers 2021 to 2025, and the forecast period is 2026 to 2032.